远大医药（00512）今日盘中大涨7.40%，引起市场广泛关注。截至下午3点38分，该股报价8.96港元，成交额达2.83亿港元。
消息面上，远大医药计划于今日（8月19日）盘后召开董事会会议，审批中期业绩。这一消息引发了投资者对公司业绩的积极预期，推动股价上涨。
值得注意的是，远大医药近期在产品研发方面取得重大突破。公司全线放射性产品钇[90Y]微球注射液获得美国FDA批准新增适应症，用于治疗不可切除肝细胞癌（HCC），成为全球首个且唯一获FDA批准用于不可切除肝细胞癌和结直肠癌肝转移双重适应症的选择性内放射治疗产品。天风证券分析认为，远大医药在核药板块已建立完整产业链，核心产品易甘泰钇[90Y]微球注射液市场前景广阔。该机构看好公司进入加速发展阶段，这也可能是投资者看好该股的另一个重要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.